Friday, February 16, 2024

Vaccine Effectiveness and COVID-19, V-Safe, and More

Received this email from a friend? Sign up now

CDC Centers for Disease Control and Prevention CDC 24/7: Saving Lives, Protecting People
Coronavirus Disease 2019 (COVID-19)
February 16, 2024
This message includes updates on respiratory viruses from CDC.

Vaccine Effectiveness and COVID-19


New data from CDC show that the updated (2023-2024) COVID-19 vaccines were effective against COVID-19 during September 2023 – January 2024, including against variants from the XBB lineage, which is included in the updated vaccine, and JN.1, a new variant that has become dominant in recent weeks. To estimate vaccine effectiveness of the updated COVID-19 vaccine, CDC analyzed data from the Increasing Community Access to Testing (ICATT) COVID-19 pharmacy testing program. The protection provided by the updated vaccine was compared to not receiving an updated vaccine, regardless of a person’s infection history or the number of previous COVID-19 vaccines received. 

Graphic of man showing his band aid

People Who Get a 2023-2024 Updated COVID-19 Vaccine Can Now Register in V-Safe


Vaccine safety monitoring is a top priority at CDC. V-safe is one of several systems CDC uses to closely monitor the safety of vaccines in the United States. V-safe registration is now open to anyone who gets a 2023-2024 updated COVID-19 vaccine or an RSV vaccine. Participants who enroll in V-safe within 6 weeks of vaccination will receive confidential health check-ins via text message or email to share how they feel after vaccination. You can sign up for V-safe using your smartphone, tablet, or computer at vsafe.cdc.gov.


Graphic of diverse group of people showing their band aids

RSV Transmission and Prevention


You can take everyday prevention measures to help reduce the spread of respiratory syncytial virus (RSV) and other respiratory illnesses. RSV immunizations are recommended for certain groups. People infected with RSV are usually contagious for 3 to 8 days and may become contagious a day or two before they start showing signs of illness. RSV can survive for many hours on hard surfaces such as tables and crib rails. It typically lives on soft surfaces such as tissues and hands for shorter amounts of time. 

graphic of a graph of covid cases

COVID-19 Testing: Is It Really Expired?


If you have an expired COVID-19 test kit, don’t throw it away. Your test kit may have a U.S. FDA–approved extended expiration date. Use FDA’s table to find out if your home test kit can still be used past the original expiration date. Home COVID-19 test kits are designed to detect all variants of COVID-19.

graphic of a graph of covid cases

Patient Support Program: Cost Savings Options Available with PAXCESS™


COVID-19 antiviral treatment can reduce the risks of hospitalization and death if you’re at increased risk of getting very sick, regardless of your vaccination status. If you get COVID-19, you should consider treatment if it is recommended for you. For patients prescribed Paxlovid, the PAXCESS Patient Support Program provides insurance verification, live PAXCESS support representatives who can help with program eligibility, and help with identifying financial assistance. Enrollment takes about 5 minutes. You can enroll online by visiting the PAXCESS website, or by phone by calling 1-877-C19-PACK (1-877-219-7225).


graphic of a graph of covid cases

CDC Tracks New SARS-CoV-2 Variant, BA.2.87.1


BA.2.87.1, a new variant of the virus that causes COVID-19, was detected in South Africa by the country’s National Institute for Communicable Diseases. CDC is closely tracking this variant because of the large number of mutations when compared to previous variants. At this time, BA.2.87.1 has not been identified in clinical specimens outside South Africa. Because this is a newly emerging variant, there is not as much additional data about its potential impact. So far, the public health risk for this new variant appears low. CDC continues to track the appearance and spread of new variants around the world through national genomic surveillance. CDC is monitoring this new variant closely and will provide updates as more information becomes available.

graphic of a graph of covid cases

Notes from the Field: Long COVID Prevalence Among Adults


Long COVID continues to impact millions of people, increasing health care needs in every U.S. state and territory. A new report shows that the percentage of U.S. adults in 2022 who reported ever experiencing Long COVID varied by U.S. state and territory, from 2% in the U.S. Virgin Islands to 11% in West Virginia. The percentage tended to be lower in New England and the Pacific, and higher in the South, Midwest, and West. Check the report to find data for your state. Clinicians and public health professionals should consider these data to inform health care and public health policy, strategy, and action to reduce the impact of Long COVID. 

Centers for Disease Control and Prevention

1600 Clifton Rd   Atlanta, GA 30329   1-800-CDC-INFO (800-232-4636)   TTY: 888-232-6348
Questions or Problems  |  Unsubscribe

Friday, January 19, 2024

COVID-19 Updates

Received this email from a friend? Sign up now

CDC Centers for Disease Control and Prevention CDC 24/7: Saving Lives, Protecting People
Coronavirus Disease 2019 (COVID-19)
January 19, 2024
Amount of Respiratory Illness Is Elevated or Increasing in Most Areas of the Country
Graphic of man showing his band aid

Respiratory Virus Data Channel Weekly Snapshot


The amount of respiratory illness (fever plus cough or sore throat) causing people to seek healthcare is elevated or increasing across most areas of the country. CDC’s Respiratory Virus Data Channel provides a summary of the key viral respiratory illness findings for COVID-19, flu, and RSV. CDC continues to anticipate this fall and winter respiratory illness season will likely result in a similar number of hospitalizations as last season. Vaccination remains the best way to protect yourself against serious outcomes of COVID-19, flu, and RSV (if eligible for RSV vaccine). 

Graphic of man showing his band aid

Where to Find FREE COVID-19 Testing 


CDC’s Increasing Community Access to Testing (ICATT) program will continue to provide no-cost COVID-19 testing for uninsured people who are symptomatic or exposed. More than 19,000 ICATT sites will also offer no-cost COVID-19 vaccines to adults without health insurance and adults without full vaccine insurance coverage. This website helps you find ICATT COVID-19 testing locations and contact information for the providers. You can also visit your state, tribal, local, or territorial health department’s website to find the latest local information on testing.


Graphic of diverse group of people showing their band aids

Benefits of Antiviral Treatment for COVID-19 Outweigh Potential Risks of Rebound


If you get sick with COVID-19 and are at higher risk for severe illness, antiviral treatments are available that can reduce your risk of hospitalization and death. But it’s important to get on treatment within 5-7 days after you first develop symptoms.


Rebound, a return of symptoms or a new positive test after having tested negative, has been reported in people with and without the use of COVID-19 antivirals. Current evidence suggests rebound presents as mild symptoms 3-7 days after initial illness resolves. If you are at high risk for severe COVID-19, treatment benefits outweigh the potential risks of rebound.


graphic of a graph of covid cases

Updated Guidance for Healthcare Providers on Increased Supply of RSV Immunization to Protect Babies


Nirsevimab is an RSV antibody immunization recommended for preventing severe RSV in infants and some young children. Supply of nirsevimab was limited earlier in the season, and CDC provided guidance to healthcare providers on how to prioritize the limited supply. But with recent increases in supply, CDC now advises healthcare providers to return to recommendations put forward by CDC and the Advisory Committee on Immunization Practices (ACIP) on the use of nirsevimab in babies and young children. Infants and children recommended to receive nirsevimab should be immunized as quickly as possible. RSV antibody immunization is recommended for all infants who are younger than 8 months, born during or entering their first RSV season, and some children between 8-19 months who are at increased risk for severe RSV and entering their second RSV season. Most infants whose mothers received an RSV vaccine do not need to also get an RSV antibody.


Centers for Disease Control and Prevention

1600 Clifton Rd   Atlanta, GA 30329   1-800-CDC-INFO (800-232-4636)   TTY: 888-232-6348
Questions or Problems  |  Unsubscribe

Vaccine Effectiveness and COVID-19, V-Safe, and More

This message includes updates on respiratory viruses from CDC. Received this email from a friend? Sign up now View this email in your web br...